Consistent with these findings, treatment of the tumour-bearing larvae with specific serotonin receptor inhibitors, such as volinanserin (which has high selectivity for the 5-HT2A serotonin receptor) or paliperidone (which has highest affinity for the 5-HT2A and 5-HT7 serotonin receptors, but can also bind to α-adrenergic receptors) (Chue and Chue, 2012; Ebdrup et al., 2011; Jones et al., 2020), did not inhibit tumour growth alone or in combination with trametinib (Fig. S7A-D). Here, HTR2A is linked to neoplasm.